Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 "EMERGE" Study


Goy A., Williams M. E., Besisik S., Drach J., Ramchandren R., Zhang L., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.14, 2014 (SCI-Expanded) identifier